DecImmune Therapeutics Receives $1,749,999 Series A Financing Round

  • Feed Type
  • Date
    1/17/2013
  • Company Name
    DecImmune Therapeutics
  • Mailing Address
    800 Huntington Ave. Boston, MA 02115
  • Company Description
    The company operates as a drug development company focused on inflammation.
  • Website
    http://www.decimmune.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,749,999
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.